Becton, Dickinson And Company

Becton, Dickinson And Company's BD Biosciences division supplies flow cytometry instrumentation, maintenance services, reagents, and laboratory consumables to federal health and research agencies as a prime contractor operating on a full-and-open, non-set-aside basis. BD Biosciences is a division of Becton, Dickinson And Co, a large for-profit global medical technology manufacturer headquartered in Franklin Lakes, New Jersey, with the BDB Division (operating as BD Biosciences) based in Milpitas, California.

BD Biosciences' federal footprint centers on flow cytometry platforms—FACSymphony, LSRFortessa, FACSLyric, FACSAria, and FACSMelody systems—and associated maintenance, repair, and consumable support. Recent representative work includes a $4.512 million firm fixed-price purchase order from the National Cancer Institute (July 2, 2026) for maintenance services covering 23 government-owned BD flow cytometers through July 1, 2030, with two annual preventive maintenance inspections, unlimited technician visits, 48-hour emergency response, and parts coverage; a $1.512 million purchase order from Veterans Integrated Service Network 12 (April 1, 2026) for a 10-color flow cytometry instrumentation system with sample preparation equipment and one option year; and a $561.476 million order from the National Institute of Dental and Craniofacial Research (July 13, 2026) for a BD FACSDiscover S8 cell sorter. The division also delivers flow cytometry reagents, antibodies, and specialized laboratory kits supporting single-cell analysis, genomics, and immunophenotyping applications across federal research institutions.

Customer concentration is heavily weighted to the National Institutes of Health enterprise. The National Institute of Allergy and Infectious Diseases leads by combined potential value at $46.6 million across 379 awards, followed by the National Cancer Institute at $31.6 million across 540 awards, the Food and Drug Administration at $17.3 million across 185 awards, the National Heart Lung and Blood Institute at $13.6 million across 206 awards, and Veterans Integrated Service Network 22 at $14.8 million across 104 awards. These five customers account for approximately 22% of combined potential value across all awards. NIH institutes dominate the award count: NIAID (379), NCI (540), NHLBI (206), and subordinate NIAID organizations collectively represent the primary federal customer base, with the Department of Veterans Affairs positioned as the second-largest customer segment through its multiple Veterans Integrated Service Networks.

BD Biosciences holds two primary parent vehicle positions anchoring federal procurement: the GSA Federal Supply Schedule GS24F2044D, which carries 2,458 task orders valued at $86.2 million in combined potential value, and the General Services Administration Multiple Award Schedule, which carries 428 task orders valued at $28.2 million. These vehicles enable streamlined delivery order issuance across federal agencies without re-competition. Additionally, BD Biosciences maintains single-award indefinite delivery contracts with specific customer agencies: a $2.1 million vehicle with Veterans Integrated Service Network 17 (awarded May 1, 2026, through April 30, 2031) for flow cytometry consumables and reagents, a $1.574 million IDV with VISN 17 (awarded August 18, 2025, through May 17, 2028) for flow cytometry systems and equipment, a $1.25 million contract with the NIH Clinical Center (awarded January 1, 2025, through December 31, 2026 with optional extensions through 2029) for BD instrumentation and reagent kits, and a $4 million Blanket Purchase Agreement with the Defense Health Agency (awarded September 15, 2025, through September 14, 2030) for laboratory reagents.

Activity has remained relatively flat across the past five years: 135 awards in 2022, 132 in 2023, 141 in 2024, 91 in 2025, and 74 in 2026 (partial year). The recompete cliff shows 105 awards totaling $18.6 million in combined potential value completing within the next twenty-four months, representing moderate recompete exposure primarily across NIH institutes and VA Veterans Integrated Service Networks where BD holds incumbent positioning on maintenance and reagent supply contracts.

BD Biosciences operates as a prime contractor on 100% of its recent awards (7,127 primes versus 10 subcontractor engagements), indicating a dominant direct-delivery posture. Service Contract Inventory data spanning FY2022–FY2025 shows $1.2 million in SCI-reportable invoiced revenue across 14 prime records, with FY2025 invoicing of $481 thousand at 0.3 FTEs, FY2024 at $444 thousand at 0.1 FTEs, and FY2023 at $291 thousand at 0.3 FTEs. On federal services contracts captured in SCI, government-paid rates run a median of $1,705.96 per hour, with a spectrum from $430.84 per hour (10th percentile) to $3,590.45 per hour (90th percentile), reflecting a mix of field technician maintenance labor and specialized engineering support. SCI reporting captures only service contracts above the $150,000 threshold and excludes goods, products, and non-federal revenue; the reported figures represent a partial view of BD Biosciences' federal activity and are substantially smaller than the vendor's total federal services or enterprise revenue.

The vendor's federal portfolio is characterized by sole-source and non-competitive award patterns reflecting original equipment manufacturer (OEM) status: most BD Biosciences maintenance contracts are awarded without small business set-asides under FAR 6.302-1 (Only One Responsible Source) or FAR Part 12 Commercial Items simplified procedures, justified by BD's exclusive manufacture of proprietary flow cytometry systems and control of firmware, software, and manufacturer-certified service protocols. The division competes on full-and-open basis across Federal Supply Schedules and GSA contract vehicles, where competing vendors can place task orders, but maintains an incumbent advantage through installed base and OEM exclusivity on maintenance and support. Recent subcontracting activity (January 2025–October 2026) shows BD Biosciences as a subcontractor to Canon USA, Government Scientific Source Inc., and The Johns Hopkins University Applied Physics Laboratory on DARPA and federal research programs, but the sub-award share remains negligible relative to the prime footprint.